Changes in pattern of immunoglobulin heavy chain gene rearrangement and MIB-1 staining before and after eradication of Helicobacter pylori in gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas are strongly associated with infection by Helicobacter pylori (H. pylori). Antibiotic treatment for H. pylori induces a sustained remission in a significant number of patients. We report here the outcome in 13 patients with gastric low-grade MALT lymphomas or suspected gastric lesions, treated for eradication of H. pylori. Patients were followed closely with sequential histological studies, polymerase chain reaction (PCR) amplification of the immunoglobulin heavy chain (IgH) gene and immunohistochemistry for MIB-1. Antibiotic therapy resulted in eradication of H. pylori in all but one case, as assessed histologically. In 12 cases with successful eradication, complete regression was observed histologically in 9 cases (75%) and no regression in 3 (25%). In 7 of 9 (78%) patients who had a complete remission, clonal bands of IgH gene detected on PCR before therapy disappeared after therapy. All 9 patients with complete regression showed a reduced number of MIB-1 positive cells, while 4 cases with no change or disease progression showed no change or increased number of MIB-1 positive cells. There was a strong relationship between density of MIB-1-positive cells and histological score. These results indicate that combination analysis of PCR of IgH and MIB-1 seems to represent a very good current approach for the diagnosis of gastric low-grade MALT lymphoma and to assess the effects of chemotherapy, especially in problematic cases.
Kanda
M
M
First Department of Pathology, School of Medicine, Fukuoka University, School of Medicine, Japan.
Suzumiya
J
J
Ohshima
K
K
Okada
M
M
Tamura
K
K
Kikuchi
M
M
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D034961:Antigens, Nuclear; D016022:Case-Control Studies; D005260:Female; D015321:Gene Rearrangement; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000032:analysis / Q000235:genetics*; D007150:Immunohistochemistry; D019394:Ki-67 Antigen; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000032:analysis*; D016133:Polymerase Chain Reaction; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D034961:Antigens, Nuclear; D007143:Immunoglobulin Heavy Chains; D019394:Ki-67 Antigen; D009687:Nuclear Proteins